Table 2.
Association of measures of adiposity with kidney function decline
| Variable | N | ΔeGFR>30% | Unadjusted OR (95% CI) | Model 1a OR (95% CI) | Model 2b OR (95% CI) |
|---|---|---|---|---|---|
| Subcutaneous fat | |||||
| Continuous (per SD=121) | 2489 | 434 | 1.2 (1.0 to 1.3) | 1.3 (1.1 to 1.4) | 1.18 (1.04 to 1.33) |
| Quartiles | |||||
| <196 | 621 | 103 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 196–267 | 619 | 97 | 0.9 (0.7 to 1.3) | 1.0 (0.7 to 1.3) | 0.9 (0.7 to 1.3) |
| 268–357 | 633 | 108 | 1.0 (0.8 to 1.4) | 1.1 (0.8 to 1.6) | 1.0 (0.8 to 1.4) |
| >357 | 616 | 126 | 1.3 (1.0 to 1.7) | 1.6 (1.1 to 2.2) | 1.4 (1.0 to 1.9) |
| Visceral fat | |||||
| Continuous (per SD=67) | 2489 | 434 | 1.3 (1.2 to 1.4) | 1.3 (1.9 to 1.5) | 1.2 (1.0 to 1.3) |
| Quartiles | |||||
| <94 | 618 | 88 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 94–132 | 626 | 89 | 1.0 (0.7 to 1.3) | 1.0 (0.7 to 1.4) | 0.91 (0.7 to 1.3) |
| 133–181 | 625 | 115 | 1.4 (1.0 to 1.9) | 1.4 (1.0 to 1.9) | 1.2 (0.9 to 1.6) |
| >181 | 620 | 142 | 1.8 (1.4 to 2.4) | 1.9 (1.4 to 2.5) | 1.38 (1.0 to 1.9) |
| R thigh intermuscular fat area, cm2 | |||||
| Continuous (per SD=6.8) | 2481 | 430 | 1.2 (1.1 to 1.3) | 1.2 (1.1 to 1.3) | 1.1 (1.0 to 1.2) |
| Quartiles | |||||
| <6.15 | 631 | 83 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 6.15–9.01 | 641 | 104 | 1.3 (1.0 to 1.8) | 1.3 (1.0 to 1.8) | 1.3 (1.0 to 1.8) |
| 9.02–13.12 | 620 | 113 | 1.5 (1.1 to 2.1) | 1.5 (1.1 to 2.1) | 1.4 (1.0 to 1.9) |
| >13.12 | 589 | 130 | 1.9 (1.4 to 2.6) | 1.9 (1.4 to 2.6) | 1.5 (1.1 to 2.1) |
| Waist circumference | |||||
| Continuous (per SD=12.5) | 2488 | 434 | 1.3 (1.2 to 1.5) | 1.3 (1.2 to 1.5) | 1.2 (1.1 to 1.4) |
| Quartiles | |||||
| <91.7 | 616 | 81 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 91.7–99.2 | 645 | 98 | 1.2 (0.9 to 1.6) | 1.2 (0.8 to 1.6) | 1.2 (0.8 to 1.6) |
| 99.3–107.1 | 631 | 118 | 1.6 (1.2 to 2.1) | 1.5 (1.1 to 2.1) | 1.4 (1.0 to 2.0) |
| >107.1 | 596 | 137 | 2.0 (1.5 to 2.7) | 1.9 (1.4 to 2.6) | 1.6 (1.1 to 2.2) |
| BMI | |||||
| Continuous (per SD=4.6) | 2489 | 434 | 1.3 (1.2 to 1.4) | 1.3 (1.2 to 1.4) | 1.2 (1.0 to 1.3) |
| Quartiles | |||||
| <24.1 | 615 | 85 | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| 24.1–26.8 | 641 | 97 | 1.1 (0.8 to 1.5) | 1.1 (0.8 to 1.5) | 1.1 (0.8 to 1.5) |
| 26.9–30.0 | 638 | 119 | 1.5 (1.1 to 2.0) | 1.5 (1.1 to 2.0) | 1.3 (0.9 to 1.8) |
| >30.1 | 595 | 133 | 1.8 (1.3 to 2.4) | 1.8 (1.3 to 2.5) | 1.5 (1.1 to 2.1) |
OR, odds ratio; 95% CI, 95% confidence interval; ref, reference; R, right; BMI, body mass index.
a
Adjusted for age, sex, race, and site.
b
Further adjusted for diabetes mellitus, systolic blood pressure, hypertension meds, albumin-to-creatinine ratio, smoking, LDL cholesterol, HDL cholesterol, oral estrogen, prevalent coronary heart disease, prevalent heart failure, and C-reactive protein. Kidney function decline was defined as eGFR-cystatin C decline >30%.